Lys Therapeutics
Lys Therapeutics is a pioneering biotechnology company focused on developing innovative treatments for neurovascular and neurodegenerative disorders, including ischemic stroke and multiple sclerosis. Their main drug candidate is a first-in-class monoclonal antibody with a groundbreaking mechanism of action targeting blood-brain barrier dysfunctions. The company prioritizes clinical development of this biotherapy as a potential game changer for patients with high unmet medical needs in neurology, aiming to address significant societal impacts.
Industries
Nr. of Employees
small (1-50)
Lys Therapeutics
56 rue Saint-Jean-De-Dieu, 69007 LYON, France
Products
Lead monoclonal antibody candidate targeting pathological protease–receptor interaction
Full-length, Fc-engineered monoclonal antibody designed to prevent pathological binding of a circulating protease to endothelial receptors, intended to restore blood–brain barrier integrity and reduce neuroinflammation in neurovascular and neurodegenerative disorders.
Lead monoclonal antibody candidate targeting pathological protease–receptor interaction
Full-length, Fc-engineered monoclonal antibody designed to prevent pathological binding of a circulating protease to endothelial receptors, intended to restore blood–brain barrier integrity and reduce neuroinflammation in neurovascular and neurodegenerative disorders.
Services
Joint projects with academic institutes, translational imaging platforms and contract research organizations to generate preclinical efficacy and mechanism-of-action data supporting clinical development.
Production and supply of clinical-grade monoclonal antibody drug substance and drug product in accordance with GMP to support regulatory preclinical studies and early clinical trials.
Joint projects with academic institutes, translational imaging platforms and contract research organizations to generate preclinical efficacy and mechanism-of-action data supporting clinical development.
Production and supply of clinical-grade monoclonal antibody drug substance and drug product in accordance with GMP to support regulatory preclinical studies and early clinical trials.
Expertise Areas
- Therapeutic monoclonal antibody development
- Antibody engineering and Fc-format optimization
- CMC and GMP biomanufacturing for biologics
- Preclinical translational development for neurovascular and neurodegenerative disorders
Key Technologies
- Monoclonal antibody engineering (humanization, maturation, Fc engineering)
- GMP biologics manufacturing and formulation (intravenous and subcutaneous)
- Preclinical animal disease models (ischemic stroke, multiple sclerosis, Parkinson’s)
- Multimodal imaging (MRI, PET, angiography) for translational readouts